Drug Overview

Tamnorzatinib is a new type of “smart” medicine designed to fight tough cancers. It belongs to a group of drugs called targeted therapies. Unlike traditional chemotherapy, which can affect many types of cells in the body, tamnorzatinib is like a guided missile. It looks for specific proteins on the surface of cancer cells that help them grow and hide from the immune system.

Doctors and scientists are currently testing tamnorzatinib in clinical trials to see how well it works against various types of cancer, especially those that have become resistant to other treatments. It is most often used in studies for patients with blood cancers or advanced solid tumors.

Generic Name: Tamnorzatinib (also known as ONO-7475).
US Brand Names: None yet. It is currently an investigational drug and has not been given a brand name.
Drug Class: Axl and Mer Tyrosine Kinase Inhibitor (TKI).
Route of Administration: Usually taken by mouth (oral) or sometimes given through a vein (intravenous) in clinical settings.
FDA Approval Status: Investigational. This means it is still being studied in clinical trials and is not yet available for general use at your local pharmacy.

What Is It and How Does It Work? (Mechanism of Action)

To understand how tamnorzatinib works, imagine a cancer cell is like a high-speed car. To keep moving and growing, the car needs a functioning engine and a driver who keeps their foot on the gas. In many cancers, two specific proteins called Axl and Mer act like the “gas pedal.”

The Role of Axl and Mer

Axl and Mer are types of enzymes known as “kinases.” Normally, these kinases help healthy cells grow and repair themselves. However, in cancer cells, these proteins can get stuck in the “on” position. This sends constant signals to the cell to divide and multiply rapidly.

Furthermore, Axl and Mer help cancer cells do two very dangerous things:

Hiding from the Immune System: They create a “shield” around the tumor that makes it invisible to the body’s natural defense cells.
Developing Resistance: When patients take other cancer drugs, the cancer cells often “learn” how to survive by switching on the Axl and Mer pathways. This is why some treatments stop working over time.

How Tamnorzatinib Blocks the Signals

Tamnorzatinib is a “dual inhibitor.” This means it can block both Axl and Mer at the same time. At a molecular level, the drug binds to these proteins and prevents them from being “turned on” (a process scientists call phosphorylation).

By turning off these light switches, tamnorzatinib does two things:

It stops the growth signals from reaching the center of the cancer cell, which can lead to the cell’s death.
It breaks down the cancer cell’s shield, allowing other treatments, like immunotherapy or chemotherapy, to reach the tumor and work more effectively.

FDA-Approved Clinical Indications

As of early 2026, tamnorzatinib is still in the testing phase and does not have official FDA approval for general use. However, it is being actively studied for the following conditions:

Oncological (Cancer) Uses:

Acute Myeloid Leukemia (AML): Specifically for patients whose cancer has returned (relapsed) or did not respond to initial treatments (refractory). It is often studied in cases with a mutation called FLT3-ITD.
Non-Small Cell Lung Cancer (NSCLC): Being tested in combination with other drugs (like osimertinib) for patients whose lung cancer has become resistant to standard “smart drugs.”
Advanced Solid Tumors: This includes various types of cancer that have spread to other parts of the body and are no longer responding to standard care.
Melanoma: Early research is looking at how tamnorzatinib can help when melanoma (skin cancer) stops responding to other targeted therapies.

Non-Oncological Uses:

Currently, there are no non-cancer uses for tamnorzatinib.

Dosage and Administration Protocols

Because tamnorzatinib is an investigational drug, the exact dose can vary depending on the specific clinical trial and the type of cancer being treated. Doctors use “Phase I” trials to find the safest and most effective dose for patients.

Patient Type	Common Dose Range	Frequency	How is it given
Monotherapy (Single Drug)	3 mg to 10 mg	Once daily	Oral or IV (Trial dependent)
Combination Therapy	6 mg (with Venetoclax)	Daily or Cycle-based	Oral (usually)
Dose Adjustments	Based on side effects	As needed	Managed by a trial doctor

Note: For patients with liver or kidney issues, doctors may start with a lower dose to ensure the body can safely process the medicine.

Clinical Efficacy and Research Results

Recent clinical studies (2020-2025) have provided promising data on how tamnorzatinib performs in difficult-to-treat cases.

Highlights from Recent Studies:

AML Success: In a Phase I/II study of patients with relapsed or refractory leukemia, researchers found that tamnorzatinib could significantly reduce the number of cancer cells in the bone marrow when used alongside other treatments like venetoclax.
Solid Tumors: Early trials for patients with advanced solid tumors showed an Overall Response Rate (ORR) of approximately 8.3%. While this number may seem small, it is significant because these patients had already failed multiple other types of treatment.
Stopping Resistance: In laboratory and animal models, tamnorzatinib successfully delayed the time it took for lung cancer tumors to grow back after initial treatment, showing its potential as a “resistance-breaker.”

Safety Profile and Side Effects

Like all powerful medicines, tamnorzatinib can cause side effects. Because it targets specific proteins, the side effects are often different from the hair loss and severe vomiting typically seen with old-fashioned chemotherapy.

Black Box Warning

None. Currently, tamnorzatinib does not have a Black Box Warning because it is not yet a fully approved drug.

Common Side Effects (>10%)

Fatigue: Feeling very tired or weak.
Changes in Blood Sugar: High blood sugar (hyperglycemia) has been reported in some patients.
Anemia: A low red blood cell count, which can make you feel short of breath.
Nausea or Diarrhea: Mild stomach upset is common.
Febrile Neutropenia: A low white blood cell count accompanied by a fever, which requires immediate medical attention.

Serious Adverse Events

Infections: Because the drug affects the immune system, some patients may develop serious infections like pneumonia or sepsis.
Liver Function Changes: Changes in liver enzymes (monitored via blood tests).
Electrolyte Changes: High potassium levels (hyperkalemia) or low phosphate levels.

Management Strategies

If you experience side effects, your medical team may “hold” the medication for a few days to let your body recover or lower your daily dose. It is very important to report any new fever or extreme tiredness to your doctor immediately.

Research Areas

Scientists are currently investigating how tamnorzatinib can be used in “Regenerative Medicine” and “Immunotherapy.” One major area of study is its effect on Cancer Stem Cells. These are special “seed” cells that can survive treatment and cause the cancer to come back years later.

Researchers believe that by blocking Axl and Mer, tamnorzatinib might make these cancer stem cells more vulnerable to the immune system. There are also ongoing studies looking at combining this drug with Stem Cell Transplants for leukemia patients to help keep the cancer from returning after the transplant.

Patient Management and Practical Recommendations

If you are participating in a clinical trial for tamnorzatinib, your healthcare team will follow a strict plan to keep you safe.

Pre-treatment Tests:

Blood Work: Full blood counts and chemistry panels to check your liver, kidneys, and blood sugar.
Genetic Testing: To confirm if your tumor has the Axl or Mer proteins that tamnorzatinib targets.
Heart Scan (EKG): To ensure your heart is healthy enough for treatment.

Precautions During Treatment:

Avoid certain medications: Some drugs can interfere with how your body processes tamnorzatinib. Always give your doctor a full list of your supplements and vitamins.
Sun Protection: Some targeted therapies can make your skin more sensitive to the sun.

“Do’s and Don’ts” List:

DO take your medication at the same time every day to keep the level of the drug in your body steady.
DO drink plenty of water to help your kidneys flush the medicine through your system.
DON’T stop taking the medicine or change your dose without talking to your trial doctor first.
DON’T ignore a fever. In cancer treatment, a fever can be a sign of a serious drop in white blood cells.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Tamnorzatinib is an investigational drug and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.